About eribulin mesylate eq to eribulin
Microtubule inhibitor anticancer medicine
Used for
- Treats unresectable or metastatic breast cancer after previous chemotherapy.
- Treats unresectable or metastatic liposarcoma after prior chemotherapy.
Usual adult dose
1.4 mg/m² by intravenous infusion over 2–5 minutes on days 1 and 8 of each 21-day cycle; dose adjustments may be needed.
Common side effects
- Low white blood cell counts and infection risk
- Tiredness and weakness
- Nausea and constipation
- Peripheral nerve damage, including numbness or tingling
Important warnings
- Can cause severe low blood counts and serious infections.
- May cause nerve damage; symptoms can worsen with treatment.
- Can prolong the heart’s electrical rhythm (QT interval).
- Treatment requires blood-count monitoring and clinician-directed dose adjustments.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for 2 weeks after the final dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for 2 weeks after the final dose.
Interactions
- Medicines that prolong the QT interval may increase abnormal heart-rhythm risk.
- Strong CYP3A4 inhibitors may increase eribulin exposure; avoid when possible.
- Strong CYP3A4 inducers may reduce eribulin exposure and effectiveness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.